ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 275

Pediatric Rheumatology Practitioners Experience with Biologics in Juvenile Dermatomyositis: Survey Results

Anjali Patwardhan1, Kelly A. Rouster-Stevens2, Harry L. Gewanter3, Grant D. Syverson4, Renee F. Modica5, Kara M. Schmidt6 and Charles H. Spencer7, 1Pediatric Rheumatology, Nationwide Childrens Hospital, Columbus, OH, 2Pediatric Rheumatologist, Emory-Children's Center, Atlanta,, GA, 3Pediatric & Adolescent HP, Pediatric & Adolescent HP, Midlothian, VA, 4Pediatric Rheumatology, Medical College of Wisconsin, Wauwatosa, WI, 5Pediatric Rheumatology, University of Florida, Gainesville, FL, 6Pediatric Rheumatology, Univ of Louisville, Louisville, KY, 7Rheumatology, Nationwide Childrens Hospital, Columbus, OH

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Abatacept, etanercept, infliximab, juvenile dermatomyositis and rituximab

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects: Pediatric Systemic Lupus Erythematosus, Pediatric Vasculitis and Pediatric Myositis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Biologic therapy is increasingly prescribed in rheumatologic disorders.  Juvenile dermatomyositis (JDM), the most common inflammatory myopathy in children, can be challenging to manage in a subset of patients.  There are multiple reports of cytokine involvement in JDM. There is a paucity of information regarding the use of biologics for JDM among pediatric rheumatology practitioners, and only one clinical trial investigating a biologic in JDM. The purpose of the study is to examine pediatric rheumatology (PR) experience in North America with biologic therapy in children with JDM

Methods: The Childhood Arthritis and Rheumatology Research Alliance JDM Subcommittee on Biologics developed a 15-question on-line survey. Of the 231 pediatric rheumatology practitioners contacted, 105 (45%) participated between 2/17-3/20/2012

Results: Over half (57%) of the respondents currently managed 1-10 patients with JDM; 10% of respondents reported ≥20 patients with JDM in their practice.  Sixty-one percent of respondents had used biologics in patients with JDM, with 32%, 5%, and 4% prescribing rituximab, etanercept and infliximab, respectively; 17% had prescribed more than one biologic.  The majority of respondents (89%) had used biologics in combination with other therapies, while 11% had used biologics as monotherapy in JDM. The biologics used by the respondants were, rituximab, infliximab, etanercept and anakinra and abatacept. Among the respondents that used biologics, uncontrolled disease was the primary rationale for prescribing this medication.  Over half of respondents used biologics after the patients failed other therapies; 11% of respondents used biologics for systemic (internal organ) involvement and 15% had used biologics for severe ulcerative disease.  Seventy-three percent of respondents that used biologics noted improvement, while 10% reported worsening disease.  Over half (53%) of respondents that used biologics noted improvement in calcinosis, while 64% reported side effects (common and uncommon).  Among the respondents that had not used biologics (39%) in JDM, 88% would use this therapy if the opportunity arose; nearly half (47%) of these respondents had not used biologics because of uncertainty regarding effectiveness in JDM.  Seventy percent of practitioners recommended that biologics be formally studied in patients with JDM; 24% of respondents were unsure and 6% felt biologics should not be studied in patients with JDM

Conclusion: Several PR have used biologics in the management of pediatric patients with JDM.  Among respondants that have not used biologics in this patient population, most would be interested in prescribing biologics.  This survey supports the rationale for considering clinical trials and consensus protocols to elucidate the safety and effectiveness of biologics in children with JDM.  Further information will be gathered by the CARRA JDM Subcommittee on Biologics through second survey to prioritize specific medications for investigation


Disclosure:

A. Patwardhan,
None;

K. A. Rouster-Stevens,
None;

H. L. Gewanter,
None;

G. D. Syverson,
None;

R. F. Modica,
None;

K. M. Schmidt,
None;

C. H. Spencer,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pediatric-rheumatology-practitioners-experience-with-biologics-in-juvenile-dermatomyositis-survey-results/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology